Protagonist Therapeutics, Inc.
PTGX
$103.88
$3.933.93%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 657.94% | 57.83% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 657.94% | 57.83% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 657.94% | 57.83% | |||
| SG&A Expenses | 16.12% | 2.73% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.85% | 13.02% | |||
| Operating Income | 92.76% | -8.47% | |||
| Income Before Tax | 105.22% | -11.13% | |||
| Income Tax Expenses | -325.53% | -- | |||
| Earnings from Continuing Operations | 108.52% | -12.82% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 108.52% | -12.82% | |||
| EBIT | 92.76% | -8.47% | |||
| EBITDA | 93.52% | -8.51% | |||
| EPS Basic | 108.38% | -12.37% | |||
| Normalized Basic EPS | 105.13% | -10.71% | |||
| EPS Diluted | 107.16% | -12.61% | |||
| Normalized Diluted EPS | 104.73% | -10.71% | |||
| Average Basic Shares Outstanding | 1.65% | 0.41% | |||
| Average Diluted Shares Outstanding | 10.09% | 0.41% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||